Royalty Pharma plc (RPRX)

Looking ahead, the outlook remains ... earnings growth, improving opportunities from market dispersion, and attractive valuations providing a margin of safety despite limited exposure to crowded themes like AI. In addition, please check the Fund’s top five holdings to know its best picks in 2025. In…

Royalty Pharma EVP Marshall Urist sold 13,684 Class A shares at a $52.75 weighted average, then held 18,197 directly and 19,020 via IRA, under a Rule 10b5-1 plan.

Royalty Pharma PLC (NASDAQ:RPRX – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $53.48 and last traded at $53.43, with a volume of 1724718 shares traded. The stock had previously closed at $53.06.

Royalty Pharma earnings and buyback ... Pharma (RPRX) has drawn fresh investor focus after reporting first quarter 2026 earnings with revenue of US$630.58 million and net income of US$294.69 million, alongside continued progress on its multi year share repurchase program. See our latest analysis for…

Why Riley Exploration Permian (REPX) Stock Is Trading Lower Today